This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

One Month Degarelix/Comparator Treatment for Prostate Cancer in Chinese Population (PANDA)

This study has been completed.
Information provided by (Responsible Party):
Ferring Pharmaceuticals Identifier:
First received: December 5, 2012
Last updated: June 22, 2015
Last verified: June 2015
One month degarelix/comparator treatment for prostate cancer in Chinese population

Condition Intervention Phase
Prostate Cancer Drug: Degarelix Drug: Goserelin Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: An Open-label, Multi-centre, Randomised, Parallel-group Trial, Comparing Efficacy and Safety of Degarelix One-month Dosing Regimen With Goserelin in Chinese Patients With Prostate Cancer Requiring Androgen Ablation Therapy

Resource links provided by NLM:

Further study details as provided by Ferring Pharmaceuticals:

Primary Outcome Measures:
  • Cumulative probability of testosterone at castrate level (≤0.5 ng/mL) [ Time Frame: Day 28 to Day 364 ]

Secondary Outcome Measures:
  • Proportion of patients with testosterone levels ≤0.5 ng/mL [ Time Frame: at Day 3 ]
  • Percentage change in prostate-specific antigen (PSA) [ Time Frame: from baseline to Day 28 ]
  • Changes in testosterone and PSA levels [ Time Frame: Day 0 to 364 ]
  • Significant changes in laboratory values [ Time Frame: Day 0 to Day 364 ]
  • Significant changes in vital signs [ Time Frame: Day 0 to Day 364 ]
  • Significant changes in body weight [ Time Frame: Day 0 to Day 364 ]
  • Frequency and severity of adverse events [ Time Frame: Day 0 to Day 364 ]
  • Cumulative probability of no PSA failure [ Time Frame: Day 0 to Day 364 ]
    PSA failure defined as two consecutive (at least two weeks apart) increase of 50 percentage and at least 5ng/mL increase compared to nadir

Enrollment: 285
Study Start Date: January 2013
Study Completion Date: May 2015
Primary Completion Date: May 2015 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Degarelix
Degarelix 240/80 mg
Drug: Degarelix
Active Comparator: Goserelin
Goserelin 3.6 mg
Drug: Goserelin


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Chinese male over 18 years
  • Adenocarcinoma of the prostate
  • Relevant disease status based on lab values and as judged by the physician
  • Life expectancy of at least a year

Exclusion Criteria:

  • Previous hormonal treatment for prostate cancer
  • Considered to be candidate for curative therapy
  • Risk or history of any serious or significant health condition
  • Has received an investigational drug within the last 28 days and no previous treatment with degarelix
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01744366

China, Beijing
Cancer Institute & Hospital. Chinese Academy of Medical Sciences
Beijing, Beijing, China
China, Chongqing
Affiliated Southwest Hospital of 3rd Military Medical University of People's Liberation Army
Chongqing, Chongqing, China
China, Guangdong
1st Afilliated Hospital of Guangzhou Medical College
Guangzhou, Guangdong, China
China, Hubei
Renmin Hospital of Wuhan University
Wuhan, Hubei, China
China, Shanxi
2nd.Affiliated Hospital of Xi'an Jiaotong University College of Medicine
Xi'an, Shanxi, China
China, Zhejiang
1st Hospital Affiliated to Zhejiang University Medical School
Hangzhou, Zhejiang, China
Beijing Hospital of Ministry of Health
Beijing, China
Peking Union Hospital
Beijing, China
Peking University 3rd Hospital
Beijing, China
Peking University People's Hospital
Beijing, China
1st Hospital of Jilin University
Changchun, China
Hunan Cancer Hospital
Changsha, China
Hunan Province People's Hospital
Changsha, China
People's Hospital of Sichuan
Chengdu, China
2nd Hospital Affiliated to Zhejiang University Medical School
Hangzhou, China
1st Hospital of Lanzhou University
Lanzhou, China
1st Affiliated Hospital of Nanchang University
Nanchang, China
1st Affiliated Hospital of Nanjing Medical University
Nanjing, China
Drum Tower Hospital Affiliated to Nanjing University Medical School
Nanjing, China
Fudan University Shanghai Cancer Center
Shanghai, China
Huashan Hospital of Fudan University
Shanghai, China
Shanghai 5th People's Hospital affilicated to Fudan University
Shanghai, China
Shanghai Changhai Hospital
Shanghai, China
1st Hospital Affiliated to China Medical University
Shenyang, China
2nd Hospital Affiliated to Suzhou University
Suzhou, China
2nd Hospital of Tianjin Medical University
Tianjin, China
Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology
Wuhan, China
Zhongnan Hospital of Wuhan University
Wuhan, China
1st People's Hospital of Wuxi
Wuxi, China
Sponsors and Collaborators
Ferring Pharmaceuticals
Study Director: Clinical Development Support Ferring Pharmaceuticals
  More Information

Responsible Party: Ferring Pharmaceuticals Identifier: NCT01744366     History of Changes
Other Study ID Numbers: 000006
Study First Received: December 5, 2012
Last Updated: June 22, 2015

Additional relevant MeSH terms:
Prostatic Neoplasms
Genital Neoplasms, Male
Urogenital Neoplasms
Neoplasms by Site
Genital Diseases, Male
Prostatic Diseases
Antineoplastic Agents, Hormonal
Antineoplastic Agents processed this record on August 22, 2017